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Background: The impact of neoadjuvant treatment and their subsequent early complications 
in the treatment of rectal cancer has not been adequately assessed. The aim of this 
prospective study was to evaluate early postoperative morbidity and mortality among patients 
with rectal cancer treated with adjuvant radiotherapy and chemotherapy followed by surgery, 
compared with patients treated with surgery alone. We also identified independent risk 
factors associated with early major complications. 
Methods: Between 1995 and 2004, 273 consecutive patients underwent treatment for rectal 
cancer. A total of 170 patients (group A) received preoperative radiotherapy with a total of 
45–50.4 Gy (180 cGy per day) and 5-fluorouracil-based chemotherapy, followed by surgery; 
103 patients (group B) were treated with surgery alone. Dependent variables related to 
patients, treatment, radiotherapy, and tumor were analyzed. 
Results: Both groups were similar with regard to age, sex, body mass index, American Society 
of Anesthesiologists (ASA) score, and tumor location but not for ileostomy (27% in group A 
vs. 6.8% in group B). The number of complications was similar in both groups (43.1% in group 
A vs. 44.6% in group B). No differences in wound infection (8.2% vs. 7.8%), intraabdominal 
abscess (4.7% vs. 4.9%), anastomotic dehiscence (4.2% vs. 3.8%), postoperative hemorrhage 
(3.5% vs. 3.9%), urinary complications (6.5% vs. 4.9%), paralytic ileus (8.9% vs. 9.7%), or 
general complications (7.1% vs. 9.6%) were found. The global mortality in the first 30 days 
after surgery was .7%. An ASA score of III–IV and surgery duration longer than 3 hours were 
identified as independent prognostic factors for early complications. 
Conclusions: Preoperative chemoradiation in patients with rectal cancer treated with surgery is 
not associated with a higher incidence of early postoperative complications. The patient~s 
preoperative clinical condition and lengthy surgery time are prognostic factors for early 
complications. 
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The therapeutic aim in rectal adenocarcinoma treatment is to attain cure, longer disease-free sur-
vival time with good quality of life, and reduction of local recurrence of disease, all while 
minimizing the risk of complications. Surgical treatment is the basis of therapy in those cases 
where good mesorectal excision is achieved, following the criteria established by Heald et al. in 
1982.1–3 On many occasions, depending on the extent of tumor, neoadjuvant chemotherapy is 
required. 
Better control of local disease, reduced therapeutic toxicity, a possible increase in the proportion 
of patients having surgery with sphincter preservation, and a slight increase in survival time are the 
advantages offered by neoadjuvant therapy in comparison with postoperative adjuvant therapy.4–10 
It seems that the response rate after treatment with preoperative chemoradiotherapy is 
approximately double that after radiotherapy alone (20% vs. 10%).10 Some specific modifications 
of the radiotherapy technique, as well as an increase in the time elapsed between the end of 
radiotherapy and surgery, may increase the number of complete responses.11
Nowadays, some surgeons consider that neoadjuvant therapy increases the incidence of early 
postoperative complications, especially causing a higher incidence of anastomotic leakage. 
However, evidence is derived only from experimental studies.12,13 Some published studies describe 
the influence of radiation on early postoperative morbidity and mortality. However, the existing 
range of methodologies, inclusion criteria, and therapeutic modalities makes it difficult to analyze 
such an influence.14–18 Some studies also show mortality associated with adjuvant combined 
therapy,19,20 as well as toxicity and surgical reintervention because of intestinal obstruction19 and 
disturbances in bowel habit and incontinence,21,22 associated with radiation. 
The purpose of this study was to analyze the early postoperative complications in a group of 
patients treated with preoperative chemoradiotherapy and surgery, as compared with another group 
treated with surgery alone, and to identify possible prognostic factors associated with postoperative 
morbidity. 
PATIENTS AND METHODS 
Design 
Between January 1995 and December 2004, 273 patients diagnosed with rectal adenocarcinoma 
(tumor margin <16 cm from the anal verge) were treated in our hospital. They were attended by a 
multidisciplinary team made up of oncologists, radiotherapists, and surgeons with a special interest 
in colorectal pathology. 
A retrospective study was performed with a data-base created with prospective information 
collected about the patients (age, sex, body mass index [BMI], and American Society of 
Anesthesiologists [ASA] score),23 the surgical procedures (type and duration of surgery, 
ileostomy, type of anastomosis and blood transfusion), radiotherapy dose, duration, and interval 
between radiotherapy and surgery), and the tumor (staged according to the tumor, node, metastasis 
system,24 and location). Diagnostic procedure and disease stratification was performed with 
abdominal and pelvic computed tomographic scan, magnetic resonance imaging, and rectal 
ultrasonic endoscopy with biopsy. All patients with a pathology diagnosis other than 
adenocarcinoma, those undergoing emergency surgery, those with coexistent malignant tumor, or 
those who had undergone previous rectal surgery were excluded. 
Patients were allocated to two different groups: group A was made up of 170 patients who were 
provided both chemoradiotherapy and surgery, and group B was made up of 103 patients treated 
with surgery alone. Neoadjuvant chemoradiotherapy was indicated for patients whose preoperative 
staging revealed tumor infiltration deeper than the muscular layer (T3) or lymph nodes suspicious of 
metastasis (N+) and in eight patients with stage T2N0 in an effort to improve the sphincter 
preservation rate. All patients not fulfilling these criteria (71 of 103) as well as those with metastasis 
(M1) (24 of 103) were included in group B, so that systemic chemotherapy would not be delayed. 
Finally, patients who refused preoperative chemoradiotherapy were also assigned to group B (8 of 
103). In 12 patients included in group A, we found intraoperative M1 disease. They were excluded 
from this study, as were patients with unresectable metastasis disease treated with preoperative 
chemotherapy. 
Preoperative Radiotherapy 
External radiotherapy techniques were delivered in two, three, and four fields according to the 
guidelines provided in Report 50 of the International Commission on Radiation Units and Measure-
ments,25 including the primary tumor and regional, mesorectal, presacral, and internal iliac (up to 
L5-S1) lymph nodes. Most of the patients (77 of 103) received a standard dose of 45–504 Gy in 25 
fractions over 5 weeks, combined with chemotherapy based on 5-fluorouracil (5-FU) boluses 
during the first and last week of radiotherapy. Fifteen patients received a reduced dose because of 
intolerance, and 11 received a dose over 50.4 Gy. All of them underwent surgery between the 
fourth and sixth week after completing radiotherapy. 
 
 
Surgical Procedures 
All the patients underwent intestinal preparation the day before surgery, as well as intestinal 
decontamination with oral antibiotic therapy, antithrombotic prophylaxis with low molecular 
weight heparin, gastric protection with ranitidine, and intravenous antibiotic prophylaxis against 
anaerobes and gramnegative bacteria. The procedures used were as follows: low anterior resection 
with mechanical anastomosis, Miles abdominoperineal amputation, and the Hartmann procedure. A 
protective ileostomy was created according to the surgeon's decision, taking into account technical 
factors, the general health of the patient, and the use of neoadjuvant therapy with 
chemoradiotherapy. In all cases, information was gathered prospectively about the duration of the 
surgical procedure, blood loss, and intraoperative blood transfusion requirements as decided by the 
anesthetists. 
Pathological examination of the surgical specimens was carried out by the same pathologist, 
who classified them according to the tumor, node, metastasis staging system. Postoperative 5-
FU-based adjuvant therapy was provided to those patients in group A found at pathological 
examination to have persistent disease. Adjuvant therapy was also suggested for those patients 
belonging to group B with stage III and IV disease. 
Complications 
Postoperative complications were recorded as follows: 1, surgical wound complications (infection, 
seroma, abscess); 2, intra-abdominal abscess; 3, anastomotic leak (considered when clinical 
symptoms and required reoperation or interventional radiology) 4, postoperative hemorrhage 
(rectorrhagia and hemoperitoneum); 5, urinary disturbances (retention, infection, dysuria); 6, general 
complications (pulmonary, cardiovascular, catheter sepsis, thrombosis); and 7, paralytic ileus 
(continued nasogastric tube on the fifth postoperative day or reintroduction of the tube). Surgical 
mortality was defined as mortality within the first 30 days after surgery. 
Statistical Analysis 
Data were collected from a computer database. Data collection was supervised by the same sur-
geon throughout the study. Data analysis was performed by SPSS 11.0 software (SPSS, Chicago, 
IL). 
 
Categorical variables were analyzed by contingency tables and x2 or Fisher exact probability, 
depending on the cases. Continuous variables were analyzed with the Student t-test. The 
association between independent variables and complications was analyzed with lineal logistic 
regression. P values below .05 were considered to be statistically significant. 
RESULTS 
Series Analysis 
The demographic characteristics of the 273 patients are shown in Table 1. The two groups were 
homogeneous in age, sex, BMI, ASA, tumor location, type of surgery, blood transfusion, duration of 
surgery, and duration of hospitalization. Differences in tumor stage between groups were caused by 
the selection groups. 
The rate of pT0 in patients treated with chemoradiotherapy was 15%. We found 31.5% of patients 
to have lymph nodes metastasis (N+), and we found positive circumferential margins in seven cases 
(four in group A). 
Most of the patients allocated to preoperative chemoradiotherapy (group A) received a standard 
dose of 45–50.4 Gy, with conventional fractioning (1.8 Gy), during a 5-week period. The mean dose 
was 4700 cGy (range, 3696–6500 cGy). Chemotherapy with 5-FU (350 mg/m2/day) was given in 
the first and last weeks of the radiation period. The average time between preoperative 
chemoradiotherapy and surgery was 8 days (range, 30–61 days). The mean radiotherapy duration 
was 36 days (range, 20–70 days). 
The characteristics of the surgical procedures in both groups, with values of statistical 
significance, are displayed in Table 1. Thirty-five percent of patients were admitted to the intensive 
care unit (ICU) after surgery. The mean duration of surgery was 170 minutes (range, 70–540 
minutes) in group A and 150 minutes (range, 45–330 minutes) in group B, which was not 
statistically significant. No statistically significant differences between the groups were found with 
regard to sphincter-preserving surgery (76.5% in group A vs. 75.5% in group B) or blood 
transfusion (16.6% in group A vs. 18.1% in group B). A total of 31.2% patients in group A 
underwent ileostomy, versus 8.8% in group B (P < .001). Other surgical procedures 
(cholecystectomy, hysterectomy, hernia surgery) were combined with the tumor excision in 13% of 
the patients in group A, versus 22.3% in group B (P < .045). 
 
 
Complications 
The complications found in both groups are listed in Table 2. Its important to note that although 
statistically significant differences were not found, the number of patients who experienced 
complications was smaller in group A (23%) than in group B (32%). However, the number of 
complications was similar in both groups (43.1% vs. 44.6%). 
Similar rates of surgical wound infection (8.2% vs. 7.8%), intra-abdominal abscess (4.7% vs. 
4.9%), suture dehiscence (4.2% vs. 3.8%), postoperative hemorrhage (3.5% vs. 3.9%), urinary 
disturbances (6.5% vs. 4.9%), paralytic ileus (8.9% vs. 9.7%), and general complications (7.1% vs. 
9.6%) were also found. All cases of anastomotic leak occurred in patients without an ileostomy. 
 The global mortality in the series was two patients (.7%), one in each group. One patient (.6%) in 
the group treated with chemoradiotherapy died of severe myocardial ischemia during the early 
postoperative period, and one patient (1%) in the group treated with surgery alone died of intra-
abdominal hemorrhage. 
Univariate analysis (Table 3) showed that those patients with ASA III–IV tumors included a 
higher number of patients with complications (P < .001), surgical wound infection (P = .023), 
paralytic ileus (P = .028), and general complications (P < .01) than ASA I–II tumors. 
Surgical procedures lasting longer than 3 hours were also associated with a higher 
proportion of patients with complications (P = .006) and wound infections (P < .001). Blood 
transfusion during surgery was associated with a significantly higher rate of intra-abdominal 
abscess (P = .004) and anastomotic dehiscence (P = .004). 
In the multivariate analysis, male sex, ASA III–IV score, surgery lasting longer than 180 minutes, 
BMI >30, the Hartmann procedure, and blood transfusion were variables significantly associated 
with a higher risk of complications (Table 4). 
 
 
DISCUSSION 
 
Neoadjuvant radiotherapy with or without chemotherapy has been widely used in patients diag 
nosed with rectal cancer to achieve better outcomes. Several controlled studies have showed a 
lower rate of local recurrence in those patients treated with a combination of radiotherapy and 
surgery.9,19,26 However, it is not easy to assess the effect of longterm radiotherapy on early 
postoperative morbidity and mortality. Potential problems related to preoperative radiotherapy are 
perianal sepsis, delayed surgical wound healing, and a higher rate of anastomotic dehiscence,26–28 
although many authors disagree, given that the use of temporary stomas without well-defined, 
universal criteria makes it difficult to analyze. A comparative analysis of the available studies is 
difficult because of the different inclusion criteria and chemoradiotherapy modalities used and 
because of variations in the standardization of surgical procedures. The aim of this study was to 
analyze the early (30 days) postoperative morbidity and mortality in patients with rectal 
adenocarcinoma, comparing two groups with similar surgical procedures, with and without 
preoperative radiotherapy. Furthermore, we assessed the prognostic factors related to those 
complications. 
Patients in both groups had homogenous characteristics concerning age, sex, BMI, ASA, tumor 
location, and type of surgical procedure. We used a long-radiotherapy protocol with treatment of 
5.4 Gy provided to the tumor, as opposed to protocols of short duration, because of the benefits 
evidenced in downstaging. In our experience, 15% of patients treated according to this protocol had 
a complete response (n = 25), as assessed by pathology. Clinical staging of the tumors with the 
currently available tools makes it unlikely that patients with low-stage disease (T1-T2N0) would be 
overstaged or that patients would have distant metastasis, especially after including endoscopic 
ultrasound, which has a sensitivity of >90%.29
It seems that the combination of both adjuvant therapies increases the rate of complications 
associated with therapeutic toxicity compared with radiotherapy alone. Although this fact could be 
related to the synergistic effect of the two modalities, the correlation between neoadjuvant toxicity 
and postoperative complications has not been clearly determined.31,32
We have found a dose- and time-dependent correlation, although it is not statistically 
significant, between radiation and some postoperative complications. When analyzed 
individually, those patients in group A with general complications, wound infection, intra-
abdominal abscesses, and anastomotic leak had received a higher mean dose of radiotherapy and 
had experienced a longer time interval between neoadjuvant therapy and surgery. 
In our own experience, and in agreement with other published studies,14,15,31–33 we consider that 
preoperative chemoradiotherapy does not increase either the number of early postoperative 
complications or the rate of surgical mortality. We should be cautious with these results because 
ours is not a randomized, double-blind study. However, taking into account the long experience of 
our team, the standardization of therapy, and the homogeneity of both groups analyzed, we believe 
that the results obtained constitute valid information for the study of complications. 
The proportion of patients with complications in the group that received chemoradiation (23%) is 
lower than that in the group that did not receive chemoradiation (32%). However, the number of 
complications was similar for both groups (43.1% vs. 44.6%). These results are in agreement with 
those published by other authors.14,15,34
As described in other published studies,26,34,35 We also found a higher rate of wound infection in 
the chemoradiotherapy group (8.8%), mainly as a result of infection of the perianal wound in those 
patients undergoing rectal amputation. However, we did not find relevant differences in the 
incidence of intraabdominal abscesses (4.7%) and anastomotic dehiscence (4.2%). These results are 
in agreement with those described by Enker et al.,36 who concluded that preoperative 
chemoradiotherapy increases the time of surgery, blood loss, and formation of pelvic abscesses but 
does not increase anastomotic dehiscence or duration of hospitalization. 
The literature shows a percentage of global anastomotic leak ranging from 0% to 17.4%,14,15,37–
42 without any differences found between groups in many of the studies.14,15,27,34,41,43 However, 
the results are difficult to compare because of the heterogeneity of the studies and the different 
meanings assigned to the term leak. The use of temporary stomas has been generally suggested 
for tumors located <6 cm from the anal verge because of the higher risk of leakage. There is 
probably a direct correlation between anastomotic leakage and lack of stoma.15,41,43 Peeters et 
al.41 associated the lack of ileostomy and pelvic drainage to a higher likelihood of anastomotic 
leak. 
Temporary protective ileostomy was performed when faced with technical difficulties during the 
anastomosis, such as lack of watertightness and incomplete donut. However, some studies have not 
demonstrated a correlation with anastomotic leak.40 In our hospital, the use of preoperative 
chemoradiotherapy was a further factor for prescribing temporary diverting ileostomy. We 
observed a slightly higher mean radiotherapy dose (4995 vs. 4700 cGy) among those patients in the 
group treated with radiotherapy in whom an anastomotic leak was detected. 
Mortality in the first 30 days after surgery was .6% for group A and 1% for group B. These results 
were similar to those described by Enker et al.,39 Heald et al.,44 and Read et al.,42 and better than 
those published in other series.45 An important factor for this may be the exclusion of patients 
undergoing emergency surgery, which is often associated with an increase in morbidity and 
mortality. This same study concludes that the risk of postoperative mortality is associated with the 
technique used in the preoperative radiotherapy; it is higher when two fields are used. The Swiss 
study30 states that postoperative mortality is associated with the total dose of radiotherapy, the time 
interval between radiotherapy and surgery, and the type of radiotherapy administered. We were un-
able to study these risk factors because of the lack of statistical power of our study, which was 
related to a low incidence of death. 
By means of multivariate analysis, we found the following independent prognostic factors for the 
development of postoperative complications: sex, ASA score, BMI, blood erythrocyte transfusion 
during the surgical procedure, Hartmann procedure, and duration of surgery. We conclude from our 
results that ASA III–IV score and a lengthy duration of surgery (>3 hours) are directly associated 
with several postoperative complications. Thus, classical preoperative and patient-dependent risk 
factors and intraoperative and surgeon-dependent factors are associated with postoperative 
morbidity and mortality. On the other hand, neoadjuvant therapy is not associated with 
postoperative complications. 
In summary, the use of neoadjuvant chemoradiotherapy in patients with rectal cancer is not 
associated with a higher rate of early postoperative complications in general and with anastomotic 
leak in particular. The patient's preoperative condition (patient state) as defined by ASA score III–IV 
and a lengthy duration of surgery are independent prognostic factors for the development of surgical 
complications. 
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TABLES 
 
 
TABLE 1. Patient, tumor, and surgical characteristics 
Characteristic 
Group A (n) 
(n = 170) 
% 
Group B (n) 
(n = 103) 
% Total (n) v % P value 
Age, y        
<51 37 21.7 13 12.6 50 18.3 .274 
51–60 46 27.1 30 29.1 76 27.8  
61–70 60 35.3 39 37.8 99 36.2  
>70 27 15.9 21 20.4 48 17.5  
Sex        
Male 116 68.2 68 66 184 67.4 .705 
Female 54 31.7 35 34 89 32.6  
BMI (kg/m2) <25 55 32.3 36 34.9 91 33.3 .737 
25–30 89 52.3 49 47.5 138 50.5  
>30 26 15.3 18 17.4 44 16.1  
ASA score        
I–II 118 69.4 76 73.8 194 71.1 .440 
III–IV 52 30.6 27 26.2 79 28.9  
Distance from anal 
verge, cm <6 
61 35.9 31 30.1 92 33.7 .513 
6–11 67 39.4 41 39.8 108 39.6  
12–16 42 24.7 31 30.1 73 26.7  
 TNM stage        
T0 25 14.7 – – 25 9.1 <.001 
T1 13 7.6 8 7.9 21 7.8  
T2 44 25.8 43 41.6 87 31.8  
T3 80 47.1 42 40.6 122 44.7  
T4 8 4.8 10 9.9 18 6.6  
N0 116 68.2 71 68.9 187 69.2 .449 
N1 42 24.7 21 20.3 63 23.3  
N2 12 7.1 11 10.6 23 8.4  
M0 158 92.9 79 76.7 237 87 .001 
M1 12 7 24 23.3 36 13  
Operation type        
LAR 121 70.6 80 76.7 199 72.9 .308 
APR 40 23.5 17 15.5 56 20.5  
Hartmann 9 5.3 6 5.8 15 5.5  
Mean (range) 
duration (min) of 
procedure 
170 (70–540) 60.8 150 (45–330) 51.7 – – .405 
Mean stay (days) 10 (5–25) – 10 (3–45)  – 10 (3–45) .287 
Diverting stoma 46 27.1 7 6.8 53 19.4 <.001 
Associated 
operation 22 12.9 23 22.3 45 16.4 .045 
Blood transfusion 28 16.4 17 16.5 45 16.4 .754 
 
BMI, body mass index; ASA, American Society of Anesthesiologists; TNM, tumor, node, 
metastasis system; LAR, low anterior resection; APR, abdominoperineal resection. 
  
TABLE 2. Postoperative complications 
Complication Group A, n (%) Group B, n (%) Total, n (%) P value 
No. of patients with 
complication 39 (22.9) 33 (32.0)    72 (26.4) .098 
Wound infection 15 (8.2) 7 (7.8) 22 (8.1) .890 
Abdominal abscess 8 (4.7) 5 (4.9) 13 (4.8) .955 
Anastomotic leak 5 (4.2) 3 (3.8) 8 (3.6) .797 
Hemorrhage 7 (3.5) 4 (3.9) 11 (3.7) .880 
Urinary complications 12 (6.5) 5 (4.9) 17 (5.9) .582 
Postoperative ileus 15 (8.9) 10 (9.7) 25 (9.2) .818 
Other 13 (7.1) 10 (9.6) 23 (8.1) .390 
Mortality 1 (.6) 1 (1) 2 (.7) .719 
 
 
 
TABLE 3. Univariate analysis of complications 
   
Variable Complication No complication P value 
No. of patients with complication 
ASA I–II 40 154 <.001 
ASA III–IV 32 47  
Operation duration 
<180 min 32 129 .006 
Operation duration 
>180 min 35 64 
 
Wound infection 
ASA I–II 11 183 .023 
ASA III–IV 11 68  
Operation duration 
<180 min 4 157 <.001 
Operation duration 
>180 min 15 84 
 
Abdominoperineal 
resection 
11 45 .002 
BMI >30 kg/m2 6 30 <.001 
Postoperative ileus 
ASA I–II 32 129 .028 
ASA III–IV 35 64  
Male 22 161 .004 
Abdominal abscess 
Hartmann 3 12 .029 
Blood transfusion 6 39 .004 
Anastomotic leak 
Blood transfusion 4 41 .004 
General complications 
ASA I–II 11 183 <.0 
ASA III–IV 11 68 01 
 
ASA, American Society of Anesthesiologists; BMI, body mass index. 
 
 
 
  
 
TABLE 4. Multivariate analysis showing factors associated 
with postoperative complications in 273 patientsa
 
Variable RR 95% CI P value 
ASA III–IV 2.43 1.34–4.42 .030 
Operation duration >180 min 2.13 1.20–3.79 .010 
Wound infection    
ASA III–IV 2.73 1.05–7.13 .039 
Operation duration >180 min 6.66 2.07–21.40 .001 
BMI >30 kg/m2 5.84 1.11–30.70 .037 
Abdominal abscess    
Hartmann 9.75 1.94–48.92 .008 
Blood transfusion 5.04 1.52–16.62 .008 
Postoperative ileus    
Male 3.85 1.10–13.41 .034 
ASA III–IV 2.32 .90–5.48 .053 
 
RR, relative risk; 95% CI, 95% confidence interval; ASA, American Society of Anesthesiologists; 
BMI, body mass index. 
a No independent prognostic factors were found for the complications of anastomotic leak and 
hemorrhage.
 
